Last 37 quarters of trend data · Healthcare · Drug Discovery Platforms
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -46.59 | — | 0.81 | — | — | — | — | 1.54 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.59 | 253.10 | 0.55 | 10.87 | 20.26 | 3.71 | 6.00 | 0.68 | 5.84 | 4.34 | 6.25 | 29.25 | — | 7.68 | 6.08 | 11.20 | 11.97 | 17.82 | 16.56 | 33.65 | 41.23 |
| — | +6729.6% | -90.9% | +1508.8% | +247.0% | -14.5% | -4.1% | -97.7% | — | -43.5% | +2.9% | +161.1% | — | -56.9% | -63.3% | -66.7% | -71.0% | -83.8% | -90.3% | -77.0% | -89.7% | |
| P/B Ratio | 1.01 | 0.99 | 0.97 | 1.75 | 1.77 | 1.10 | 0.88 | 0.77 | 2.46 | 3.03 | 3.19 | 4.85 | 3.81 | 2.32 | 2.86 | 2.85 | 3.22 | 3.81 | 3.34 | 4.93 | 5.55 |
| — | -10.5% | +10.1% | +126.8% | -27.9% | -63.7% | -72.4% | -84.1% | -35.4% | +30.4% | +11.6% | +70.4% | +18.3% | -39.0% | -14.4% | -42.2% | -41.9% | -23.9% | -48.3% | -5.5% | +0.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 9.65 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 0.70 | — | — | — | — | 1.51 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 0.72 | — | — | — | — | 1.32 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.0% | 80.0% | 96.4% | 92.9% | 87.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.8% | 93.3% | 103.9% | 95.1% | 97.1% | 94.8% | 94.5% | 93.7% | 94.4% | 92.1% | 94.1% |
| — | -20.0% | -3.6% | -7.1% | -12.6% | 0.0% | +2.3% | +7.2% | -3.8% | +5.2% | +0.7% | -1.6% | +10.0% | +1.5% | +2.8% | +2.9% | +0.4% | -6.3% | -5.6% | -7.9% | -5.9% | |
| Operating Margin | -43.8% | -11820.0% | 65.7% | -401.9% | -754.7% | -104.5% | -319.2% | 37.8% | -98.3% | -58.9% | -63.4% | -329.2% | 383.5% | -213.6% | -136.9% | -269.8% | -198.4% | -193.7% | -194.7% | -217.7% | -206.8% |
| — | -11207.3% | +120.6% | -1162.8% | -667.7% | -77.5% | -403.5% | +111.5% | -125.6% | +72.4% | +53.7% | -22.0% | +293.3% | -10.3% | +29.7% | -23.9% | +4.1% | +61.9% | +79.4% | +71.3% | +89.4% | |
| Net Margin | -30.8% | -10780.0% | 67.8% | -369.2% | -709.5% | -83.8% | -273.2% | 43.9% | -76.2% | -48.0% | -46.0% | -274.3% | 359.2% | -185.0% | -122.2% | -252.0% | -218.2% | -199.4% | -207.1% | -239.2% | -201.5% |
| — | -12768.4% | +124.8% | -940.9% | -831.3% | -74.4% | -493.8% | +116.0% | -121.2% | +74.0% | +62.3% | -8.9% | +264.6% | +7.2% | +41.0% | -5.3% | -8.3% | +60.4% | +77.4% | +67.9% | +89.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.2% | -10.0% | 35.7% | -14.0% | -13.5% | -6.0% | -9.6% | 13.6% | -7.9% | -8.3% | -5.8% | -10.9% | -27.7% | -13.9% | -13.7% | -15.2% | -14.0% | -10.2% | -10.0% | -8.4% | -6.6% |
| — | -67.5% | +470.2% | -203.5% | -71.8% | +27.9% | -65.7% | +224.1% | +71.6% | +40.3% | +57.4% | +28.2% | -98.3% | -35.7% | -36.1% | -80.7% | -110.9% | -53.3% | -19.6% | -29.2% | +32.4% | |
| ROA | -8.9% | -8.4% | 25.6% | -8.4% | -8.6% | -4.0% | -6.4% | 7.9% | -4.0% | -4.0% | -2.8% | -5.5% | -13.1% | -6.0% | -5.9% | -6.7% | -6.4% | -4.8% | -4.8% | -4.1% | -3.3% |
| — | -110.0% | +499.8% | -206.5% | -116.1% | +0.5% | -126.8% | +243.7% | +69.5% | +32.7% | +52.1% | +17.7% | -105.8% | -23.8% | -21.9% | -62.2% | -91.4% | -16.0% | +36.3% | +29.5% | +60.4% | |
| ROIC | -22.4% | -9.7% | 31.4% | -15.5% | -13.9% | -6.7% | -9.8% | 10.1% | -9.0% | -9.5% | -7.5% | -14.3% | -35.5% | -15.3% | -14.7% | -15.0% | -11.5% | -8.9% | -7.9% | -6.4% | -6.6% |
| — | -44.9% | +420.2% | -253.2% | -55.3% | +29.4% | -31.0% | +170.8% | +74.7% | +37.7% | +48.9% | +5.1% | -208.6% | -71.0% | -85.9% | -133.9% | -75.5% | -39.6% | +17.3% | +65.7% | +82.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -12.1% | -10.2% | +36.5% | +18.8% | +557.5% | +364.4% | +273.1% | +256.2% | -70.7% | -64.0% | -56.4% | -50.2% | -7.8% | +3.3% | +4.1% | +52.2% | +46.1% | -2.5% | -16.4% | +0.2% | |
| Debt / EBITDA | — | — | 0.05 | — | — | — | — | 0.14 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.92 | 8.39 | 7.91 | 5.44 | 4.92 | 5.70 | 5.64 | 4.58 | 4.64 | 4.17 | 3.62 | 4.94 | 4.98 | 3.26 | 3.44 | 4.06 | 4.20 | 5.33 | 5.78 | 6.12 | 5.93 |
| — | +47.2% | +40.2% | +18.9% | +5.9% | +36.9% | +55.7% | -7.4% | -6.7% | +28.0% | +5.1% | +21.8% | +18.5% | -39.0% | -40.4% | -33.7% | -29.2% | -38.2% | -61.5% | -62.8% | -58.5% | |
| Quick Ratio | 4.92 | 8.39 | 7.91 | 5.44 | 4.92 | 5.70 | 5.64 | 4.58 | 4.64 | 4.17 | 3.62 | 4.94 | 4.98 | 3.26 | 3.44 | 4.06 | 4.20 | 5.33 | 5.78 | 6.12 | 5.93 |
| — | +47.2% | +40.2% | +18.9% | +5.9% | +36.9% | +55.7% | -7.4% | -6.7% | +28.0% | +5.1% | +21.8% | +18.5% | -39.0% | -40.4% | -33.7% | -29.2% | -38.2% | -61.5% | -62.8% | -58.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -783.45 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 37 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ARVN stock.
Arvinas, Inc.'s current P/E is -46.6x. The average P/E over the last 1 quarters is 0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arvinas, Inc.'s current operating margin is -43.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arvinas, Inc.'s business trajectory between earnings reports.